Myelodysplastic Syndromes, Dendritic Cell, Hypomethylating Agents, Immunotherapy
Conditions
Brief summary
The purpose of this study is to optimize the traditional treatment scheme and explore the cure scheme for the elderly by combining the existing mature treatment technology. The primary aim of this innovative immunotherapy using WT1/hTERT/Survivin-loaded DCs is to determine whether this novel DC vaccination is safe and can significantly prevent clinical relapse and increase survival of MDS patients.
Detailed description
Objective Myelodysplastic syndrome (Myelodysplasticsyndromes,MDS) is a highly age-related malignant clonal disease of the hematological system, which is characterized by pancytopenia and transformation to leukemia. In China, the median age of onset of MDS is 70 years old, and the incidence increases with age. It is the most common malignant tumor in the elderly, which seriously threatens the health and survival of the elderly. The 3-year survival rate of traditional combination chemotherapy or demethylation therapy is less than 20%.
Interventions
BIOLOGICALDC vaccine
EDC cell therapy collection and administration process. Collection of PBMC for preparation of DC cells for patients with autologous DC cells, patient PBMC was collected 10-16 weeks before administration for the preparation and large-scale culture of DC cells. For the patients with matched DC cells, a small amount of peripheral blood was taken for HLA typing 4 weeks before administration, and then the matched DC cells were cultured on a large scale.
Sponsors
Affiliated Hospital to Academy of Military Medical Sciences
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
60 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. elderly MDS patients; 2. aged more than 60 years old, general condition, ECOG score less than 1; 3. normal function of heart, liver and kidney, serum bilirubin ≤ 35 umol / L; serum creatinine ≤ 150 umol / L; 4. patients are unsuitable or unwilling to receive hematopoietic stem cell transplantation; 5. subjects sign informed consent.
Exclusion criteria
1. serious infection was not controlled before treatment; 2. contraindications for the use of dexitabine and azacytidine; 3. other cases that did not meet the admission criteria.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| OS | at study completion, an average of 3 years | Overall survival |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| the Incidence of Treatment Adverse Events | at study completion, an average of 3 years | The primary objective of this single-arm phase I clinical study is to determine the Incidence of Treatment Adverse Events in elder MDS or MDS/AML patients. |
| RR | at study completion, an average of 3 years | Relapse rate |
| RFS | at study completion, an average of 3 years | Relapse-free survival |
Countries
China
Contacts
Primary ContactYao Sun, M.D., Ph. D.
Backup ContactYuxin Wang, M.D.
Outcome results
None listed